Tulip Diagnostics Pvt. Ltd, an in-vitro diagnostic firm, has acquired Mumbai-based Biosense Technologies Pvt. Ltd, a medical devices maker, for an undisclosed sum of money. The acquisition will also provide an exit to private equity investors in Biosense such as Insitor and Menterra, and other angel and venture capital investors in the company, Tulip said in a statement. Mumbai-based 7i Capital Advisors acted as the exclusive sell-side advisor to Biosense and all its shareholders on the transaction. Abhishek Sen, co-founder and chief executive officer at Biosense, said the move would allow the two companies to combine their product portfolio and allow its customers to access the latest technologies in the in-vitro diagnostics segment at an affordable cost. “This acquisition also further expands Tulip’s footprint in the point-of-care diagnostics market directly reaching to clinics and doctors across India,” 7i Capital Advisors executive director and partner Manoj Patkar added. Biosense, which was founded in 2008, produces innovative and customer-centric point-of-care technological devices. Its products include the SYNC Glucometer; Uchek, a smartphone-based portable diagnostics s...